Market Overview

UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review

Share:
Related PFE
Swedish Orphan Biovitrum AB Confirms Receipt of Preliminary and Conditional Non-binding Proposal for Acquisition of All Shares Issued by Company
U.S. Tech, Dollar & Health Care ETFs To Watch This Week
BioMarin completes rolling NDA submission for drisapersen for DMD (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), but lowered the price target from $33.00 to $32.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Pfizer closed on Thursday at $27.48.

Latest Ratings for PFE

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Mar 2015Deutsche BankMaintainsBuy
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...